Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Esketamine/Healthy Volunteers

Esketamine for Healthy Volunteers

1 paper and 4 clinical trials exploring esketamine as a treatment for healthy volunteers.

Compounddissociative

Esketamine

Esketamine (Spravato) is the S-enantiomer of ketamine, approved as an intranasal treatment for treatment-resistant depression and MDD with acute suicidal ideation. It is administered under clinical supervision with post-dose monitoring and has reached over $1.6 billion in annual sales.

Full Esketamine profile
IndicationApproximately 300 million people affected by depression worldwide.

Healthy Volunteers

Research involving healthy volunteers has expanded to investigate the therapeutic potentials of various psychedelics for mental health conditions. Recent findings, emphasizing compounds like psilocybin and DMT, illustrate a promising future for psychedelic-assisted therapies.

Full Healthy Volunteers profile

Academic Research

1 paper
Paywallmeta

Acute effects of ketamine and esketamine on cognition in healthy subjects: A meta-analysis

This meta-analysis assessed the effects of ketamine administration in healthy participants (n=1,041) on several cognitive domains. Deficits in verbal learning/memory were most prominent, whereas response inhibition was the least affected. Negative effects were dependent on infusion dose and plasma level but unaffected by enantiomer type, route of administration, sex or age.

Published
August 1, 2022
Journal
Progress in Neuro-Psychopharmacology and Biological Psychiatry
Authors
Zhornitsky, S., Pelletier, R., Assaf, R., Potvin, S., Li, C-S., Tourjaman, V.

Clinical Trials

4 trials
CompletedPhase I

KF2024#1-trial: Esketamine Interaction Study

This open-label, Phase I trial (n=12) will investigate the effects of different methods of esketamine administration (28 mg nasal spray vs. 28 mg oral solution) with and without CYP3A4 inhibitors (grapefruit juice or cobicistat) on drug absorption and metabolism.

Started
December 9, 2024
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
NCT06726382
CompletedPhase NA

(GluEsk) Glutamate and Esketamine (GluEsk)

Randomised, double-blind, within-subject crossover study (n=16 actual) assessing single-dose intranasal esketamine 56 mg versus placebo on dynamic brain glutamate release, resting-state connectivity, and vision in healthy volunteers.

Started
June 1, 2024
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT06432322
CompletedPhase I

A Phase I Randomized, Placebo Controlled, Double-Blind, Single-Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of PCN-101 (Arketamine) and a Relative Safety Comparison of PCN-101 and Esketamine in Healthy Volunteers

Phase I, randomized, double-blind, placebo-controlled study in healthy volunteers assessing single ascending IV doses of PCN-101 (arketamine) and a crossover relative safety comparison with esketamine (15 mg IV).

Started
February 25, 2020
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
ACTRN12620000226909
Unknown statusPhase I

Imaging Neural Correlates of Ketamine Using PET/MR

Randomized, placebo-controlled, double-blind crossover PET/MR study (n=65) comparing IV racemic ketamine and IV esketamine versus placebo in healthy adults to investigate pharmacodynamic differences using [18F]FDG PET/MR.

Started
January 10, 2020
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT04587778

Explore further

Search all Esketamine papers Search all Healthy Volunteers trials Full Esketamine profile Full Healthy Volunteers profile